Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.

Cancer discovery - 3 Apr 2023

Weng Weining, Meng Tao, Zhao Qianqian, Shen Yi, Fu Guoxiang, Shi Jing, Zhang Yue, Wang Zhaohui, Wang Mingqiao, Pan Rong, Ma Linjie, Chen Caiwei, Wang Lijun, Zhou Biao, Zhang Hui, Pu Junyi, Zhang Jianjian, Hu Yi Peter, Hua Guoqiang, Qian Yu, Liu Shu-Hui, Hu Wenhao, Meng Xun

Abstract excerpt

Antibody-drug conjugates (ADC) using DNA topoisomerase I inhibitor DXd/SN-38 have transformed cancer treatment, yet more effective ADCs are needed for overcoming resistance. We have designed an ADC class using a novel self-immolative T moiety for traceless conjugation and release of exatecan, a more potent topoisomerase I inhibitor with less sensitivity to multidrug resistance (MDR). Characterized by enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Colon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoconjugates

Share to Irinotecan

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Topoisomerase I Inhibitors

Source

Identifiers

PMID: 36693125
DOI: 10.1158/2159-8290.CD-22-1368

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody-Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer.PMID 36693125Read ↗

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read ↗

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read ↗

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read ↗

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

Antibody-Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Peptide-drug conjugates bearing an antimitotic Ahx-DA1 payload achieve potent antitumor activity in Her2-amplified and EGFR-positive KRAS-mutant cancers in vivo.Semantic proximity Read ↗

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read ↗

Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor GrowthSemantic proximity Read ↗

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug DiscoverySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.